MedPath

Validation of Radioisotope Guided Lymphadenectomy for Loco-regional Staging in Patients With Intermediate or High-risk Prostate Cancer

Not Applicable
Completed
Conditions
Patient With Prostate Cancer
Interventions
Procedure: standard lymphadenectomy
Procedure: lymphadenectomy radio-isotope method
Registration Number
NCT02732392
Lead Sponsor
Assistance Publique Hopitaux De Marseille
Brief Summary

The diagnosis of a ganglionic infringement(achievement) at a patient reached (affected) by a prostate cancer is a factor(mailman) of bad forecast. The locoregional ganglionic staging is a very important element in the coverage (care). He allows to determine the local extension of the disease and the type(chap) of therapeutics to implement(operate) after the surgery. The standard cleaning out at present recommended by the European company (society) of urology at the patients at intermediate or high risk of second offense (recurrence) after local treatment(processing), has to concern the obturating pit, the internal and external iliac territories. However this type(chap) of cleaning out does not seem to solve all the problems of locoregional stratification. Indeed, several studies concerning the radio-controlled cleaning out highlighted that 10 in 30% of ganglions.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
177
Inclusion Criteria
  • Subject man, whose age is greater than or equal to 18 years
  • Carrier of cancer intermediate risk non-metastatic prostate or high relapse
  • Subject with an initial balance sheet expansion, regional and general negative by Scanner, abdominopelvic MRI or bone scan,
  • Subject has undergone a medical examination in connection with the study,
  • Topic for which a radical prostatectomy is considered curative purposes,
  • Supported by Subject surgical teams involved in the study,
  • Topic affiliated to a social security scheme,
  • Subject who signed informed consent.
Exclusion Criteria
  • Subject man, whose age is less than 18 years
  • Subject who have received hormone therapy or radiation therapy for prostate cancer
  • Subject who had surgery for prostate adenoma (transurethral resection or open surgery) because of potential difficulties injection of radioactive tracer in the gland,
  • Subject has a history of pelvic surgery or radiotherapy,
  • Subject with inguinal hernia repair history of laparoscopic,
  • Subject refusing blood transfusions,
  • Subject is not agreeing to participate in this study and did not sign the informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
lymphadenectomystandard lymphadenectomy-
lymphadenectomylymphadenectomy radio-isotope method-
Primary Outcome Measures
NameTimeMethod
Number of sentinel nodes radiolabeled54 months

Number of sentinel nodes radiolabeled outside the standard cleaning of territory

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Assistance Publique HĂ´pitaux de Marseille

🇫🇷

Marseille, France

© Copyright 2025. All Rights Reserved by MedPath